Skip to main content

Table 3 Multivariate logistic regression of the 5-year disease free status in relation to the poor-prognosis score and other clinical variables

From: Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts

  All events (n = 159) (number of events = 38)
  Odds ratio (95% confidence interval) P value
Poor-prognosis score 4.19 (1.49–11.77) 0.007
Age (per 10 years) 1.11 (0.79–1.54) 0.55
Stage
   Stage 2 versus 1 1.28 (0.4–4.08) 0.68
   Stage 3 versus 1 1.11 (0.42–2.95) 0.83
Elston grade
   Grade 2 versus 1 3.32 (0.63–17.56) 0.16
   Grade 3 versus 1 2.81 (0.5–15.74) 0.24
Estrogen-receptor-positive 2.94 (0.76–11.28) 0.12
Progesterone-receptor-positive 0.35 (0.12–0.99) 0.05